Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) – Stock analysts at Jefferies Group reduced their FY2021 earnings estimates for Sucampo Pharmaceuticals in a research note issued on Wednesday. Jefferies Group analyst D. Steinberg now forecasts that the biopharmaceutical company will earn $1.78 per share for the year, down from their previous estimate of $1.86. Jefferies Group currently has a “Hold” rating and a $11.00 price target on the stock.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.06. The company had revenue of $59.90 million for the quarter, compared to analysts’ expectations of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The business’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.24 EPS. TRADEMARK VIOLATION NOTICE: “Sucampo Pharmaceuticals, Inc. to Post FY2021 Earnings of $1.78 Per Share, Jefferies Group Forecasts (NASDAQ:SCMP)” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/07/sucampo-pharmaceuticals-inc-to-post-fy2021-earnings-of-1-78-per-share-jefferies-group-forecasts-nasdaqscmp.html.

Several other analysts also recently weighed in on SCMP. Roth Capital set a $30.00 price target on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. BidaskClub downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. TheStreet downgraded Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Finally, ValuEngine downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Sucampo Pharmaceuticals has an average rating of “Buy” and an average price target of $17.63.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 0.721% during midday trading on Monday, hitting $10.475. The stock had a trading volume of 43,535 shares. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $17.55. The firm’s market cap is $483.88 million. The firm has a 50 day moving average of $10.58 and a 200 day moving average of $10.73.

A number of institutional investors have recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System boosted its position in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 100 shares during the last quarter. First Citizens Bank & Trust Co. acquired a new position in Sucampo Pharmaceuticals during the second quarter worth $116,000. Karp Capital Management Corp acquired a new position in Sucampo Pharmaceuticals during the first quarter worth $119,000. SG Americas Securities LLC boosted its position in Sucampo Pharmaceuticals by 5.6% in the second quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 631 shares during the last quarter. Finally, Capstone Asset Management Co. boosted its position in Sucampo Pharmaceuticals by 2.1% in the second quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 260 shares during the last quarter. 58.20% of the stock is owned by institutional investors.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.